Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act (S.2296/H.R.3838); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
2025 · 3rd Quarter (July 1 - Sep 30)
EISAI, INC.
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 18, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- CROSSROADS STRATEGIES, LLC
- Client
- EISAI, INC.
- Filing UUID
- 73b87ce2-faa0-4b01-81a3-f5141d4acd66
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21).
Literal federal measure citations: H.R.1
H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.
Literal federal measure citations: H.R.1
Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.